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Synthetic microparticles conjugated with VEGF165
improve the survival of endothelial progenitor cells
via microRNA-17 inhibition
Sezin Aday1,2,3,4, Janet Zoldan5, Marie Besnier4, Laura Carreto6, Jaimy Saif4, Rui Fernandes7, Tiago Santos8,
Liliana Bernardino8, Robert Langer3, Costanza Emanueli4,9 & Lino Ferreira1,2
Several cell-based therapies are under pre-clinical and clinical evaluation for the treatment of
ischemic diseases. Poor survival and vascular engraftment rates of transplanted cells force
them to work mainly via time-limited paracrine actions. Although several approaches,
including the use of soluble vascular endothelial growth factor (sVEGF)—VEGF165, have been
developed in the last 10 years to enhance cell survival, they showed limited efﬁcacy. Here, we
report a pro-survival approach based on VEGF-immobilized microparticles (VEGF-MPs).
VEGF-MPs prolong VEGFR-2 and Akt phosphorylation in cord blood-derived late outgrowth
endothelial progenitor cells (OEPCs). In vivo, OEPC aggregates containing VEGF-MPs show
higher survival than those treated with sVEGF. Additionally, VEGF-MPs decrease miR-17
expression in OEPCs, thus increasing the expression of its target genes CDKN1A and ZNF652.
The therapeutic effect of OEPCs is improved in vivo by inhibiting miR-17. Overall, our data
show an experimental approach to improve therapeutic efﬁcacy of proangiogenic cells for the
treatment of ischemic diseases.
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Ischemic diseases are leading cause of morbidity and mortalityin the contemporary world. Several pre-clinical and clinicaltrials are exploring the therapeutic effect of cell-based
therapies, in particular, bone marrow-derived proangiogenic
cells and mesenchymal stem cells in ischemic diseases1–3.
Unfortunately, most of the cells (more than 80%) die a few days
(< 3 days) after delivery4–6, thus hindering the therapeutic effect.
Some approaches have been explored to augment cell survival in
ischemic conditions. These include the exposure of transplanted
cells to temperature shock, genetic modiﬁcation of cells to
overexpress growth factors and/or anti-apoptotic proteins and
pre-conditioning the cells with pharmacological agents and
cytokines7, 8. However, most of these methodologies have not
reached the clinical trials, because they have shown limited
effectiveness due to the multi-factorial nature of cell death. In
addition, some of them are not cost-effective (e.g., recombinant
proteins) or are difﬁcult to implement from a regulatory stand-
point (e.g., genetic modiﬁcations).
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Fig. 1 Preparation of VEGF-MPs and biological characterization in OEPCs. a Schematic representation of the protocol for the preparation of VEGF-
conjugated particles and b for the formation of cell aggregates containing sVEGF or VEGF-MPs. c Light microscopy images of the OEPC aggregates at 24 h.
The differences in color of cell aggregates are due to the presence of MPs. Bar corresponds to 50 μm. d VEGFR-2 phosphorylation in OEPC aggregates
cultured in media containing sVEGF. e VEGFR-2 phosphorylation in OEPC aggregates containing VEGF-MPs or containing cell culture media exposed to the
same number of MPs used to make the cell aggregates [(VEGF-MPs)SN]. VEGF phosphorylation was quantiﬁed by ELISA. Values are given as average±
SEM (n= 4–8). f, g ELISA quantiﬁcation of phospho-Akt/total Akt (f) and phospho-p38/total p38 (g). Values are given as average± SEM (n= 3).
In d, statistical analyses were performed using one-way ANOVA followed by a Bonferroni post test. In e–g, unpaired t-test was performed between groups.
*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, and ****P≤ 0.0001
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Vascular endothelial growth factor 165 (from now on referred
as VEGF) is one of the most powerful and well-studied
pro-survival/pro-angiogenic factors9, 10. Three main tyrosine
kinase receptors initiate signal transduction cascades in response
to soluble VEGF, including VEGF receptor 1 (VEGFR-1),
VEGFR-2, and VEGFR-310, 11. VEGF exerts its pro-survival effect
mostly via VEGFR-2 by inducing its dimerization and subsequent
phosphorylation of the receptor12. Although soluble and
immobilized VEGF induce similar degrees of VEGF receptor
phosphorylation, they have different properties13. In comparison
to endothelial cells (ECs) cultured in the presence of soluble (free)
VEGF (sVEGF), ECs cultured on VEGF-bound surfaces show
different morphology14, extended VEGFR-2 phosphorylation
(mediated by the phosphorylation at the site Y1214 of
the VEGFR-2 C-terminal tail)13, and higher activation of the p38/
MAPK pathway13. Due to the prolonged VEGFR-2
phosphorylation and higher activation of subsequent pathways,
immobilized VEGF might be a promising pro-survival agent for
cell-based therapies. However, in vitro and in vivo pro-survival
effects of immobilized VEGF remain relatively elusive. In
addition, the downstream molecular players mediating the
biological effect of immobilized VEGF, particularly micro RNAs
(miRNAs), are still unknown.
Herein, we have engineered microparticles (MPs) with VEGF
and studied the pro-survival effect and function of VEGF-MPs
in outgrowth endothelial progenitor cells (OEPCs). We have
additionally investigated the involvement of miRNAs in the
biological responses to immobilized VEGF. Previous studies on
the differential signaling responses of immobilized VEGF focused
on planar surfaces that are not transplantable in most cases,
thus making the identiﬁcation of in vivo molecular players of
immobilized VEGF difﬁcult13, 15. Here, we have immobilized
VEGF onto magnetic MPs of 4.5 μm, which can be assembled
with OEPCs in cell aggregates and are transplantable. In this
study, we have used umbilical cord blood CD34+ cell-derived
OEPCs3. In contrast to the “early” endothelial progenitor
cells, OEPCs directly participate in tubulogenesis16 and their
neovasculogenesis properties have been demonstrated in
pre-clinical tests using different animal models of hindlimb
ischemia, diabetic chronic wounds, among others4, 5, 17–19.
Moreover, although OEPCs express endothelial cell markers such
as vWF and VECAD; uptake acetylated LDL; and display the
morphology of ECs, they show distinct features from mature
ECs6, 20.
We show that VEGF-MPs assembled into cell aggregates
prolong the phosphorylation of VEGFR-2 and Akt in OEPCs in
comparison to sVEGF. Furthermore, VEGF-MPs incorporated in
cell aggregates increase OEPC survival both in vitro and in vivo as
compared with cell aggregates, cell aggregates containing
either uncoated MPs or sVEGF. We further show that the
prolonged VEGFR-2 phosphorylation in cell aggregates
containing VEGF-MPs is associated with the down-regulation of
miR-17 and increase in the expression of its target genes
CDKN1A and ZNF652.
The bioengineering platform used in this work opens an
avenue to improve the mechanistic understanding of how VEGF
immobilization alters cell behaviors and what are the molecular
mediators of this process, thus enabling the design of previously
undescribed therapies to treat ischemic diseases.
Results
VEGF can be immobilized onto magnetic MPs. VEGF
was immobilized onto magnetic MPs (4.5 µm diameter) using
biotin-streptavidin chemistry (Fig. 1a). The biotin-streptavidin
system is the strongest noncovalent biological interaction
known21. In this method, streptavidin-coated MPs were ﬁrst
conjugated with biotinylated anti-histidine (anti-his) antibody,
and then, with histidine-tagged VEGF (his-VEGF). To determine
the success of VEGF immobilization, MPs were separated by a
magnet, washed (until no measurable leaching of VEGF was
observed), and then exposed to a ﬂuorescent secondary antibody
against immobilized VEGF followed by ﬂow cytometry
characterization. Streptavidin-coated MPs conjugated with
biotinylated anti-his antibody in the absence of his-VEGF showed
no ﬂuorescence (Supplementary Fig. 1a). In contrast, VEGF-MPs
showed an increase in the mean ﬂuorescence indicating that MPs
were successfully conjugated with VEGF. Then, we evaluated
different initial ratios of anti-his antibody and his-VEGF to
maximize the concentration of immobilized VEGF. Depending
on the initial concentrations of antibody and growth factor,
the immobilized VEGF amounts were between 271.8± 44.3 and
425.4± 50.2 ng per 106 microparticles (Supplementary Fig. 1b).
For subsequent studies, MPs conjugated with 425.4± 50.2 ng
VEGF per 106 particles were used.
MPs do not induce toxicity in OEPCs. The toxicity of MPs
against OEPCs was determined by cell proliferation, viability, and
apoptosis assays. Firstly, iron release studies from the MPs were
performed by inductively coupled plasma mass spectrometry
(ICP-MS). It is known that MPs might have potential toxic effects
especially due to iron release from them22–24. Polstyrene-coated
MPs were used in our studies to prevent this iron release. Indeed,
no release of Fe from MPs was determined up to 7 days in cell
culture medium at 37 °C (Supplementary Fig. 1c). In order to
evaluate the effect of MPs on cell proliferation, monolayers of
OEPCs were used (Supplementary Fig. 2a). The cells were treated
with different ratios of MPs (1:10–1:100; cell:MP ratios) up to
5 days and cell proliferation was quantiﬁed by a WST-1 assay.
No measurable effect of MPs on cell proliferation was observed
(Supplementary Fig. 2a). Then, cell viability was monitored in cell
aggregates having different cell numbers and cell:MP ratios
(Supplementary Fig. 2b, c). Cell aggregates with small number of
cells (≤10,000 cells) having a cell:MP ratio of 1:1 showed lower
survival than cell aggregates without MPs (Supplementary
Fig. 2b). Therefore, for subsequent experiments we have used cell
aggregates with 20,000 cells having a diameter of approximately
150 μm (Fig. 1c). Then, we evaluated the cell:MP ratio. Cell
aggregates with a cell:MP ratio of 1:1 seem to survive slightly
better than the ones with a cell:MP ratio of 1:2 and thus were
selected for subsequent experiments (Supplementary Fig. 2c).
After selection of cell number and cell:MP ratio, we checked
whether MPs increased apoptosis in cell aggregates. The MPs did
not induce apoptosis in cell aggregates as determined by a
TUNEL assay (Supplementary Fig. 2d, e).
VEGF-MPs induce VEGFR-2 phosphorylation and increase
[Ca2+]i. The extracellular distribution of VEGFR-2 clusters was
initially monitored to evaluate the effect of VEGF-MPs on
VEGFR-2. VEGF-MPs induced VEGFR-2 clustering at the
cell surface and the clustering was prolonged relatively to
sVEGF (Supplementary Fig. 3a, b). To determine the activity of
VEGF-MPs, we evaluated the phosphorylation level of VEGFR-2.
OEPCs were starved for 20 h, harvested and suspended in basal
medium containing either sVEGF or VEGF-MPs. In order to
improve cell–MP interaction, the cell suspension was then seeded
in hanging drops and incubated for different period of times
(Fig. 1b, c). Cell aggregates without MPs or cell aggregates with
uncoated MPs were used as controls. Cell aggregates treated with
the same amount of sVEGF showed a rapid increase in the
phosphorylation of VEGFR-2 (Fig. 1d) and returned to its basal
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level after 10 min. In contrast, cell aggregates with VEGF-MPs
showed high levels of VEGFR-2 phosphorylation for at least 30
min (Fig. 1e).
To conﬁrm that the phosphorylation of VEGFR-2 was
mediated by the immobilized VEGF, but not VEGF leaching
from the MPs, VEGF-MPs were suspended in cell culture
medium at the same concentration used in cell aggregates and
incubated at 37 °C for 30 min. After incubation, the MPs were
removed and starved OEPCs were suspended in MP conditioned
medium to generate hanging drops. No increase in VEGFR-2
phosphorylation was observed when VEGF-MP conditioned
medium was used (Fig. 1e). These results conﬁrm that the
phosphorylation of VEGFR-2 in OEPC aggregates containing
VEGF-MPs was mediated by the immobilized VEGF.
Phosphorylation and dephosphorylation of ligated or free
VEGFR-2 occur on the cell surface and in the endosomes25.
Computational models indicated that Rab4/5 endosomes contain
more VEGFR-2 phosphorylated at the Y1175 site while the cell
surface has more VEGFR-2 phosphorylated at the Y1214 site25.
Previously, it was shown that VEGF conjugated onto ﬂat surfaces
extended the phosphorylation of the VEGFR-2 at the Y1214 site
and activated p38/MAPK pathway13. In our study, OEPCs
internalize VEGF-MPs (Supplementary Figs. 3c and 4a), which
may alter the phosphorylation proﬁle of tyrosine residues in
VEGFR-2. The phosphorylation of Y1175 and Y1214 peaked after
3–5 min for sVEGF treated group. A similar proﬁle was observed
for the phosphorylation of Y1214 in VEGF-MP-treated group,
while the phosphorylation of Y1175 peaked at 10 min and
maintained its levels for additional 50 min (Supplementary
Fig. 5a, b). In line with Y1175 phosphorylation results, the
phosphorylation of Akt was prolonged in VEGF-MP treated
group relatively to sVEGF one (Fig. 1f). Finally, in agreement
with previous studies, p38 phosphorylation was prolonged in
VEGF-MP treated group than in sVEGF treated group13 (Fig. 1g).
To further evaluate the bioactivity of VEGF-MPs, we assessed
their capacity to increase intracellular free Ca2+ via activation
of VEGFR-226 (Fig. 2a). The phosphorylation of VEGFR-2
activates PLCγ, which in turn activates MAPK/ERK-1/2 pathway
and also increases the intracellular levels of Ca2+. In ECs,
the initial increase in the cytosolic-free calcium is due to Ca2+
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Fig. 2 The biological effect of VEGF-MPs on OEPCs. a Single cell calcium measurements. OEPCs were starved in medium without serum for 20 h, loaded
with a Ca2+ probe and activated by VEGF, blank MPs, VEGF-MPs, or inhibited by Vatalanib, an inhibitor of VEGFR-2. The arrows indicate the time when the
compounds or MPs were added. At least 10 cells have been monitored for intracellular Ca2+ in each of the experimental groups. Averages and SEM values
are in black and grey, respectively. b Schematic representation of the protocols used to demonstrate the higher OEPC survival and activity after exposure to
VEGF-MPs than sVEGF. c, d The survival (c 24 h) and apoptosis (d 12 and 24 h) of OEPCs in aggregates under hypoxia in serum-deprived conditions as
assessed by an ATP-based assay or the measurement of caspase 9 activity. e, f OEPC aggregates were cultured on Matrigel under hypoxia for 12 and 60 h,
after which the tube length (e) and branching points (f) were measured. MPs indicate cell aggregates containing uncoated beads while (VEGF-MPs)SN
indicates cell aggregates exposed to the supernatant of VEGF-MPs. In all graphs, values are given as average± SEM (n= 3–8). Statistical analyses were
performed using one-way ANOVA followed by a Bonferroni post test. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, and ****P≤ 0.0001
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mobilization from intracellular stores and only afterwards is due
to extracellular Ca2+ inﬂux26. To monitor intracellular levels
of Ca2+ on single cell level, OEPCs were starved in basal
medium without supplements for 20 h and loaded with the
calcium-sensitive ﬂuorescent dye, Fura-2 AM. Firstly, the cells
were activated by sVEGF (Fig. 2a). The administration of VEGF
induced a fast increase in intracellular free Ca2+ after 3 min,
peaking at 4–5 min, followed by a decrease in the intracellular Ca2
+ (6–7 min) and a plateau phase where Ca2+ remains constant for
the remaining of the experiment (at least 9 min). The rapid
response to sVEGF is due to the fast interaction of VEGF with its
receptor and the internalization of the receptor-ligand complex26.
In contrast to sVEGF, VEGF-MPs stimulated the OEPCs
continuously for a longer time. In our experiments, changes
were followed up to 45 min and an oscillation in Ca2+ was
observed for the cells stimulated with VEGF-MPs (Fig. 2a).
Importantly, no changes in the intracellular Ca2+ levels were
observed for cells exposed to blank MPs. When VEGFR-2
inhibitor Vatalanib was used, the signal was abolished for the cells
treated with VEGF-MPs.
Overall, immobilized VEGF, but not sVEGF, prolongs the
phosphorylation of VEGFR-2 in OEPCs. This effect seems to be
associated with a prolongation in the phosphorylation of tyrosine
site Y1175 and the phosphorylation of Akt. In addition,
immobilized VEGF prolongs the phosphorylation of p38 as
previously reported13. The phosphorylation of VEGFR-2
by immobilized VEGF also induced a prolonged intracellular
Ca2+ increase that was abolished by chemically inhibiting
VEGFR-2 with Vatalanib.
VEGF-MPs enhance in vitro and in vivo survival of OEPCs.
Next, we evaluated whether VEGF-MPs could enhance the
survival of OEPCs cultured under hypoxic conditions (0.5% O2),
to mimic the environment that cells encounter after transplan-
tation in ischemic tissues. MPs were mixed with a suspension of
OEPCs and cell aggregates were formed by a hanging drop
methodology27 (Fig. 2b). At 24 h, cell aggregates containing
VEGF-MPs showed 60% higher ATP production (and thus
indirectly cell viability) than cell aggregates treated with sVEGF
(Fig. 2c). This effect was likely related to the prolonged activation
of pro-survival Akt pathway in VEGF-MPs compared to sVEGF
groups. Cell aggregates containing VEGF-MPs were also less
susceptible to apoptosis. After 12 h (but not at 24 h) under
hypoxia, caspase 9 activity was lower for the cell aggregates
exposed to sVEGF or containing VEGF-MPs than aggregates
containing blank MPs (Fig. 2d). Moreover, TEM results at 24 h
conﬁrmed that OEPC aggregates containing VEGF-MPs showed
less stress- and cell death-related lipid droplets15 (Supplementary
Fig. 4b–d) and lysosomes16 (Supplementary Fig. 4e) than the ones
containing blank MPs, sVEGF, or MPs (Supplementary
Fig. 4b–e).
VEGF-MPs also enhanced the stabilization of vascular
networks formed by OEPCs when cultured on top of Matrigel.
To evaluate the angiogenic potential of OEPC aggregates with
and without VEGF-MPs, cell aggregates were cultured on top of
Matrigel under hypoxia (0.5% O2). The Matrigel assay showed
differences in the interaction of VEGF-MPs or blank MPs with
OEPCs. Most of the VEGF-MPs were in close contact with
OEPCs (Supplementary Fig. 5c, d), while a signiﬁcant number of
blank MPs were dispersed throughout well and not in the vicinity
of sprouting OEPCs. The network length and branching points
were then assessed. The highest network length and number of
branch points were observed in cell aggregates exposed to sVEGF
and VEGF-MPs (Fig. 2e, f). Importantly, the highest long-term
stability of the networks was achieved when VEGF-MPs were
used. After 60 h, the number of branch points decreased more
than 50% for all the conditions, while the decrease was only 30%
for cells activated by VEGF-MPs (Fig. 2f).
To demonstrate the in vivo survival effect of VEGF-MPs, cell
aggregates containing 1 × 106 GFP-expressing OEPCs with
uncoated MPs, VEGF-MPs, or sVEGF were mixed with a ﬁbrin
gel precursor solution and injected subcutaneously in mice.
OEPC survival was monitored by an IVIS system (Fig. 3a).
Animals treated with the OEPC aggregates containing blank MPs
showed a rapid decrease in the ﬂuorescence signal, which was lost
at 3 day post-transplantation (Fig. 3a, b). Similarly, animals
treated with OEPC aggregates containing sVEGF showed a rapid
decrease in the ﬂuorescence signal demonstrating a relatively
poor cell survival. However, the animals treated with the OEPC
aggregates containing VEGF-MPs showed a ﬂuorescence signal
until day 10 supporting the hypothesis that VEGF-MPs improve
the survival of transplanted cells.
Overall, in vitro, immobilized VEGF enhanced OEPC survival
in hypoxia conditions compared to sVEGF. This effect was
characterized by a reduction in cell apoptosis as conﬁrmed by a
decrease in caspase 9 activity. Our results further indicate that
immobilized VEGF has higher in vivo pro-survival effect than
sVEGF in OEPC aggregates transplanted subcutaneously into
nude mice.
VEGF-MPs modulate miR-17, and miR-217 expression. The
miRNA expression proﬁle of OEPC aggregates was determined
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following 2 h activation with uncoated MPs, VEGF-MPs, or
sVEGF by microarray (Fig. 4a). We further analyzed miRNAs
that exhibited a signiﬁcant expression difference (P< 0.05; t-test
was performed using MeV software28) in OEPC aggregates con-
taining VEGF-MPs relatively to the other groups (including
sVEGF) (Fig. 4b; Supplementary Fig. 6; Supplementary Data 1
and 2). Twenty miRNAs were downregulated in OEPC aggregates
containing VEGF-MPs while one miRNA was upregulated
(Supplementary Fig. 6). We initially focused our attention on hsa-
miR-217 and hsa-miR-17, because: (1) they were among the most
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assessed by Presto-Blue assay. f, h Transfected OEPCs or HUVECs with Ctrl amiR or amiR-17 were cultured on Matrigel for 48 h under hypoxia after which
the tube length and branching points were measured. In all graphs, values are given as average± SEM (n= 4). An unpaired t-test was performed for
statistical analysis between Ctrl amiR and amir-17 groups. *P≤ 0.05, **P≤ 0.01, and ***P≤ 0.001
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downregulated miRNAs in cell aggregates containing VEGF-MPs
relatively to cell aggregates containing sVEGF (Supplementary
Data 1), (2) downregulation of hsa-miR-217 and hsa-miR-17 has
been associated with the prevention of vascular ageing29 and
enhancement of angiogenic activity30, (3) qRT-PCR results
conﬁrmed that miR-17 and miR-217 were signiﬁcantly
downregulated when the VEGF‐MPs were incubated with cells
for a short time (2 h) (Fig. 4c).
Next, we investigated whether a similar trend in the expression
of hsa-miR-217 and hsa-miR-17 could be found in vivo. Cell
aggregates containing 1 × 106 OEPCs were subcutaneously
injected in mice and retrieved 1 day after the surgeries (Fig. 4a).
qRT-PCR results showed downregulation of miR-217 expression
in both sVEGF and VEGF-MP treated OEPC aggregates
compared with OEPC aggregates treated with uncoated MPs.
However, miR-17 expression was uniquely downregulated only in
the VEGF-MP treated group (Fig. 4d). Altogether, our results
suggest that miR-17 downregulation might be involved in the
pro-survival effect of VEGF-MPs in OEPCs. For this reason, we
focused our further studies on miR-17.
AntagomiR-17 increases OEPC survival and angiogenesis. In
order to mimic the downregulation of miR-17 by immobilized
VEGF, OEPCs were transfected with antagomiR-17 (amiR-17)
using Lipofectamine® RNAiMAX and OEPCs survival was
evaluated after 48 h in hypoxic conditions (0.1% O2). As controls,
we used human umbilical vein ECs (HUVECs) to understand
whether the effect of amiR-17 was speciﬁc to OEPCs or it could
be a broader pro-survival molecule for both progenitor
and mature ECs, thus increasing the therapeutic potential of
VEGF-MPs. miR-17 downregulation after amiR-17 transfection
in OEPCs and HUVECs was conﬁrmed by qRT-PCR
(Supplementary Fig. 7a). Cell viability assay showed that
amiR-17 increased the survival of both cell types in hypoxia
(Fig. 4e, g). Moreover, amiR-17 increased the angiogenic
responses in both OEPCs and HUVECs under hypoxic
conditions compared to control amiR-treated groups (Fig. 4f, h).
Next, we investigated whether the aforementioned positive effects
of miR-17 inhibition in OEPCs were relevant for the therapeutic
performance of the cells after their transplantation in mouse
ischemic limbs. Indeed, pre-treatment of OEPCs with amiR-17
before transplantation accelerated the post-ischemic hemody-
namic recovery (Fig. 5) and increased the capillary density of
ischemic limb 21 days after the surgery (Fig. 5c–e).
The prevalent function of a miRNA is to inhibit the translation
of a series of mRNA targets (usually called miRNA target
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“genes”). To deﬁne the target genes of amiR-17 in OEPCs, we
used next generation mRNA sequencing (Fig. 6a; Supplementary
Fig. 7b, c; Supplementary Tables 3–6). mRNAs that were
upregulated by amiR-17 were chosen as direct target genes of
the miR-17. These included: (1) ZNF652 (zinc ﬁnger protein 652),
which has a tumor suppressive function31, (2) SATL1 (spermi-
dine/spermine N1-acetyl transferase-like 1 protein), which has a
role in the ubiquitination and degradation of HIF-1a which in
turn has a critical role in angiogenesis32, and (3) CDKN1A
(cyclin-dependent kinase inhibitor 1 A, also known as p21),
which has a critical role in cell survival33 (Fig. 6b; Supplementary
Fig. 7b, c). PCR-based validation conﬁrmed that both ZNF652
and CDKN1A transcripts were up-regulated in OEPCs transfected
with amiR-17 vs cells transfected with control amiR. We
additionally analyzed previously validated miR-17 targets,
although our sequencing data did not show amiR-17 to alter
their expression (Fig. 6c). In both OEPCs and HUVECs,
downregulation of miR-17 by its inhibitor (amiR-17) increased
the expression of several genes, including endothelial differentia-
tion gene S1PR1 and JAK1, which is important in vascular
homeostasis. Next, we investigated whether these changes in gene
expression driven by amiR-17 in OEPC could be replicated by
treatment with VEGF-MPs. Indeed, as compared with either
sVEGF or uncoated MP treated groups, VEGF-MPs upregulated
CDKN1A in OEPC aggregates both in vitro and in vivo (Fig. 6d,
e). We additionally conﬁrmed the upregulation of CDKN1A
protein in OEPCs following amiR-17 treatment (Supplementary
Fig. 8). Overall, these results suggest that VEGF-MPs increase the
survival of OEPCs by downregulating miR-17 and subsequently
upregulating its target genes, particularly CDKN1A.
CDKN1A and ZNF652 regulate pro-survival effect of amiR-17.
To conﬁrm the direct binding of miR-17 to CDKN1A and
ZNF652, we used a luciferase assay to co-transfect cells with
individual 3′-untranslated region (UTR)-reporter constructs
along with a miR-17 mimic (to overexpress miR-17) (Fig. 7a).
We further tested the functions of CDKN1A and ZNF652 in
OEPCs. OEPCs were double-transfected with either CDKN1A
small interfering RNA (siRNA), ZNF652 siRNA, or control
siRNA in combination with either amiR-17 or control amiR.
The silencing for each target was conﬁrmed at mRNA level
(Supplementary Fig. 9a) and for CDKN1A in protein level
(Supplementary Fig. 9b). The treatment of OEPCs with siRNAs
against these gene targets prevented the prosurvival effect
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that amiR-17 had on OEPC exposed to hypoxia (Fig. 7b, c).
In line with these functional data, the gene expression levels of
the pro-apoptotic CASP3 and CASP9 were decreased by amiR-17,
with this response being prevented by concomitant CDKN1A
silencing (Supplementary Fig. 10a). Interestingly, OEPC
aggregates containing VEGF-MPs also showed a decrease in these
genes both in vitro and in vivo (Supplementary Fig. 10b, c).
Moreover, CDKN1A siRNA, but not ZNF652 siRNA, prevented
the in vitro angiogenesis response to amiR-17 (Supplementary
Fig. 11).
Discussion
In this study, we have investigated the pro-survival effect of
immobilized VEGF in OEPCs. After demonstrating the bioac-
tivity of immobilized VEGF by phosphorylation of
VEGFR-2 and induction of the intracellular accumulation of
Ca2+, we showed that immobilized VEGF enhanced the survival
of OEPCs both in vitro and in vivo. We have further identiﬁed
that these positive responses to immobilized VEGF in OEPCs are
mediated by a decrease in miR-17, resulting in increased
CDKN1A (p21) and ZNF652 expressions (Fig. 7d).
We have used the VEGF-MPs to identify molecular targets
mediating the prolonged pro-survival effect of immobilized
VEGF in OEPCs. Our MP-based system has several advantages
over planar surfaces with immobilized VEGF13, 14, 34. First,
our MPs can be easily conjugated or manipulated by magnetic
devices. Second, VEGF-MPs can be incorporated into cell
aggregates for in vivo transplantation and the downstream targets
of VEGF can be evaluated in an in vivo setting. Magnetic MPs
were chosen in this study because they are easily controlled by a
magnet facilitating the synthesis and puriﬁcation of VEGF-MPs
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and the characterization of cell aggregates containing VEGF-MPs
(removal of the MPs from cell lysates in western blot and RNA
isolation studies). To prevent potential toxic effects of these MPs
due to iron release22–24, we have used polystyrene-coated iron
oxide MPs. Our results indicate no signiﬁcant effect in OEPC
viability after MP uptake. It was also reported that the injection of
high doses of iron (3000 μmol Fe kg−1; 168 mg Fe kg−1) to rats
and beagle dogs did not induce any acute or subacute toxicity35.
In our study, less than 1 mg Fe kg−1 mice was injected in animal
studies.
Our results indicate that VEGF-MPs induce a prolonged
phosphorylation of VEGFR-2 and maintain high intracellular
levels of Ca2+ as compared to sVEGF. It has been shown
previously that the extended phosphorylation on planar surfaces
with conjugated VEGF is mediated by the phosphorylation at
the site Y1214 of the C-terminal tail of VEGFR-213. Both
matrix-bound and soluble VEGF activate several pathways at
similar kinetics except for p38. Conjugated VEGF showed higher
and prolonged activation kinetics for p38 compared with
soluble VEGF13. These studies indicated that some pathways are
preferentially selected according to the VEGF afﬁnity to the
matrix, VEGF presentation and the intracellular trafﬁcking of
VEGFR-213, 25. However, due to the internalization of MPs by
the OEPCs in our system, the prolonged pY1175 might
activate survival pathways, such as Akt. As an expected result of
prolonged activity, immobilized VEGF augmented the survival of
OEPC aggregates in hypoxia.
Although some biological aspects of immobilized VEGF have
been explored, no study targeted the use of immobilized VEGF to
improve cell survival both in vitro and in vivo13, 14. Previous
studies have shown that VEGF immobilized on different
substrates including titanium, ﬁbrin, and collagen is superior to
sVEGF in promoting EC proliferation36, 37 and EC branching22.
In addition, a previous study has shown that VEGF physically
immobilized to cell culture substrates could mediate EC survival
after exposure to tumstatin, a proapoptotic agent38. However, no
side-by-side comparison of the prosurvival effect of immobilized
VEGF and sVEGF has been done and no in vivo prosurvival
effect of immobilized VEGF has been reported. In this work, we
have demonstrated the prosurvival effect of immobilized VEGF
in both in vitro and in vivo. Subcutaneous injections of cell
aggregates containing VEGF-MPs revealed that immobilized
VEGF is functional in vivo and it enhances cell survival to a
greater extent than sVEGF.
We have investigated miRNAs as the molecular targets of
immobilized VEGF. Our in vitro and in vivo results show that the
dowregulation of miR-17 is important for enhanced OEPC
and EC survival. miR-17 was shown to control cellular
proliferation and apoptosis by targeting the E2F family of
transcription factors39, 40. Individual members of miR-17-92a
cluster, e.g., miR-17, reduced EC sprouting whereas inhibitors of
these miRNAs augmented angiogenesis in vitro and in vivo
by targeting JAK130. The JAK/STAT signaling pathway plays a
critical role in the vascular homeostasis and disease. Interestingly,
it was shown that inhibition of miR-17 did not affect tumor
angiogenesis, indicating a context-dependent regulation of
angiogenesis by miR-17 in vivo30. Our results indicated that
another target of miR-17, CDKN1A, was upregulated both in vitro
and in vivo when amiR-17 or conjugated VEGF was used.
Although CDKN1A is well-known as a cell-cycle inhibitor,
it has diverse biological activities such as EC survival and
migration33, 41. In the literature, it was shown that CDKN1A gene
transfer prevents apoptosis both in vitro and in vivo, following
the interruption of blood ﬂow33. In line, we have showed that the
silencing of CDKN1A using siRNA reduces amiR-17-mediated
OEPC survival and angiogenesis by upregulating apoptosis-
related genes such as CASP3 and CASP9 and increasing caspase 9
activity. In summary, the present work suggests that immobilized
VEGF might increase OEPC survival by downregulating miR-17
and subsequently upregulating CDKN1A and ZNF652, which are
direct targets of miR-17.
The transcriptional activation of the miR-17-92a cluster upon
sVEGF treatment was reported in the literature and the activation
of this cluster as a unit was reported to induce proliferation and
angiogenic sprouting20, 42. However, in these studies, the authors
did not investigate the function of individual members of
this cluster. It is known that miR-17-92a cluster has both
pro-angiogenic and anti-angiogenic miRNAs and its regulation of
angiogenesis is context dependent30, 43. These previous works
also showed that the miR-17-92a cluster activation by sVEGF
is time and cell dependent44. The results show no statistically
signiﬁcant change in the miRNA levels of miR-17-5p after 6 h and
12 h44. This might be the reason why sVEGF does not induce
miR-17 expression in our system in vitro. It was also shown that
VEGF stimulates the expression of miR-17-92a cluster in human
macrovascular venous ECs as well as in mouse microvascular
lung ECs, but not in arterial ECs44. Overall, context-, cell-, and
time-dependent regulation of miR-17-92a cluster might explain
the differences between our results and these studies.
In conclusion, we show that VEGF-MPs improve the
survival and angiogenesis of OEPCs both in vitro and in vivo.
Immobilized VEGF prolonged the VEGFR-2 phosphorylation
and Akt signaling up to 1 h, which were diminished in 10 min
when sVEGF was used. VEGF-MPs promoted OEPC survival up
to 10 days in subcutaneous injections. Our work also reveals
that miR-17 is an important molecular target of VEGF-MPs in
OEPCs. The downregulation of miR-17 both in vitro and in vivo
is associated with an up-regulation of CDKN1A and ZNF652
transcripts. Our study provides insights about the molecular
mechanism of immobilized VEGF in terms of OEPC angiogenesis
and survival.
Methods
Preparation of VEGF-conjugated magnetic MPs. Histidine-tagged VEGF
(his-VEGF; ProSpec-Tany TechnoGene Ltd., Ness-Ziona, Israel) was immobilized
onto polystyrene-coated, streptavidin-bound magnetic MPs (CELLection Biotin
Binder Kit, Thermo Fisher Scientiﬁc, Waltham, MA, USA) conjugated with
biotinylated anti-histidine antibody (R&D Systems, Minneapolis, MN, USA;
Supplementary Table 1). A schematic representation of the conjugation method
is given in Fig. 1a. Brieﬂy, biotinylated anti-histidine antibody (1.5 µg per 106
particles) solution in 0.1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich, St.
Louis, MO, USA) was added to a suspension of streptavidin-coated MPs at room
temperature. After 30 min of interaction on a rotator, the MPs were removed
from suspension by a magnet and washed three times with phosphate-buffered
saline (PBS) containing 0.1% BSA. Then, the MPs were resuspended in his-VEGF
solution (500 μl; 4.5 µg in 0.1% BSA per 106 MPs) for 30 min at room temperature
on a rotator. Subsequently, the MPs were removed from suspension by a magnet
and washed with PBS containing 0.1% BSA until no measurable leaching of VEGF
was observed. The conjugated MPs were stored in PBS at 4 °C until use.
Determination of the immobilized VEGF amount onto MPs. In order to
calculate the amount of his-VEGF immobilized onto magnetic MPs, a VEGF
ELISA kit (PeproTech EC Ltd., Rocky Hill, NJ, USA) was used according to
manufacturer’s instructions. The amount of his-VEGF conjugated to MPs was
obtained by subtracting the measured amount of his-VEGF in the washing
solutions from the original amount of his-VEGF added to the MPs.
Flow cytometry analysis of magnetic MPs. Conjugation of VEGF to magnetic
MPs was conﬁrmed by ﬂow cytometry. After the conjugation step, MPs were
blocked with BSA (2% (w/v); Sigma-Aldrich) for 30 min at 25 °C, washed, and then
stained with phycoerythrin (PE)-conjugated anti-human VEGF antibody (R&D
Systems) for 45 min at room temperature, in the dark (Supplementary Table 1).
Uncoated and anti-his antibody-coated particles (without VEGF) were used as
controls. FACScan (BD Biosciences, San Diego, CA, USA) and BD Cell Quest
Software (BD Biosciences, Franklin Lakes, NJ, USA) were used for the acquisition
and analysis of the data.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00746-7
10 NATURE COMMUNICATIONS |8:  747 |DOI: 10.1038/s41467-017-00746-7 |www.nature.com/naturecommunications
Determination of iron release from magnetic MPs. ICP-MS was performed to
determine the amount of Fe release from magnetic MPs. Brieﬂy, MPs (106 MPs)
were added into 1 ml 0.1% (w/v) BSA (Sigma-Aldrich) in PBS. Subsequently, the
MPs were removed from suspension by a magnet and washed one more time with
PBS containing 0.1% BSA. Then, cell culture medium (500 μl; EGM-2; Lonza,
Gaithersburg, MD, USA) was added onto MPs and they were incubated at 37 °C up
to 7 days. The release medium was collected from n= 3 samples at different time
points (1, 2, 3, 5, and 7 days). MPs and cell culture medium were used as controls.
Differentiation of CD34+ cells into OEPCs. Human UCB sample collection was
approved by the ethical committees of Dr. Daniel de Matos Maternity Hospital in
Coimbra and Hospital Infante D. Pedro in Aveiro. Parents signed an informed
consent form indicating the use of collected UCB in research, in compliance
with Portuguese legislation. CD34+ cells were isolated from human UCB and
differentiated into OEPCs4, 31. Brieﬂy, CD34+ cells were cultured in EGM-2
medium (Lonza) supplemented with 20% (v/v) fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA) and 50 ng ml−1 of VEGF165 (PeproTech Inc.,
Rocky Hill, NJ, USA), on 1% gelatin-coated 24-well plates (2 × 105 cells per well).
After 2–3 weeks of differentiation, cells were characterized by immunoﬂuorescence
to conﬁrm their OEPC phenotype. For each experiment, the cells were expanded in
1% (w/v) gelatin-coated T75 ﬂasks (BD Biosciences, Franklin Lakes, NJ, USA) in
EGM-2 (Lonza) medium.
Preparation of OEPC aggregates. Conﬂuent OEPC cultures (until passage 7)
were detached and suspended in serum reduced EGM-2 (1% FBS; v/v) medium
without VEGF that contains 20% (w/v) methocel27, 45. The methocel solution
was prepared by dissolving carboxymethylcellulose (6 g) in EBM-2 basal medium
(500 ml). After centrifugation, the gel-like supernatant was used for experiments.
Cells suspended in methocel solution (20,000 cells per 30 µl of methocel solution)
were seeded into nonadhesive bacteriological dishes (Greiner, Frickenhausen,
Germany; in drops of 30 µl) and cultured at 37 °C (5% CO2, 95% humidity) for 12
h. Under these conditions, suspended OEPCs formed spontaneous aggregates.
After 12 h, cell aggregates were collected and transferred into untreated 384-well
plates (Nunc, Penﬁeld, NY, USA) containing ﬁbrinogen solution. Fibrin gels were
formed by crosslinking of ﬁbrinogen in the presence of thrombin (both from
Sigma-Aldrich). The ﬁbrinogen solution was prepared by dissolving human
ﬁbrinogen (20 mgml−1) in Tris-buffered saline (TBS) (Sigma-Aldrich) at pH 7.4,
and then sterilized by ﬁltering through a 0.22 µm syringe ﬁlter (Acrodisc, Pall, NY,
USA). Fresh thrombin solutions were prepared by dissolving human thrombin in
TBS at pH 7.4 at a concentration of 50 Uml−1. Fibrin gels (30 µl) were prepared by
mixing three different components: ﬁbrinogen (10 mgml−1), CaCl2 (Merck,
Kenilworth, NJ, USA; 2.5 mM) and thrombin (2 Uml−1). This solution was
allowed to jellify at 37 °C and 95% relative humidity. After the solidiﬁcation of the
gel, serum-reduced (1% FBS; v/v) EGM-2 medium without VEGF was added into
each well, on the top of the ﬁbrin gels. The cells were then incubated at 37 °C and
5% CO2 under hypoxia conditions (0.5% O2) for 24 h.
Toxicity studies for MPs. To evaluate the effect of MPs on cell proliferation,
OEPCs were seeded on 1% gelatin-coated 96-well plates and cultured with different
ratios of MPs (1:10, 1:25, 1:50, and 1:100; cell:MP ratios) up to 5 days and the
kinetics of proliferation was evaluated using cell proliferation reagent WST-1
(Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s
instructions. This monolayer model was chosen due to the fact that cells in
spheroids do not proliferate. For viability tests, cell spheroids with different cell
numbers and cell:bead ratios were prepared as described above. The viability of
the cells was determined up to 5 days using the CellTiter-Glo® luminescent cell
viability assay (Promega, Madison, WI, USA) according to manufacturer’s
instructions (as described below).
TUNEL stainings. Apoptotic cell death in cell aggregates and cell aggregates
treated with blank MPs was determined using In Situ Cell Detection Kit according
to the manufacturer’s instructions (Roche, Mannheim, Germany). This kit is
based on labeling of DNA strand breaks by terminal deoxynucleotidyl transferase
(TdT) and detection of incorporated ﬂuorescein labels in nucleotide polymers by
ﬂuorescence microscopy. Brieﬂy, cell aggregates were prepared as described in
previous sections. After 24 h in hanging drops, cells were seeded into gelatin-coated
24-well μ-Plates from IBIDI (Munich, Germany) and incubated 24 h under
hypoxia conditions (0.1% O2). After incubation, the media were removed; cells
were washed twice with PBS and ﬁxated with 4% paraformaldehyde (EMS,
Hatﬁeld, PA, USA) for 15–20 min at room temperature. Cells were rinsed with PBS
and incubated in permeabilization solution (0.1% Triton X-100 in 0.1% sodium
citrate) for 2 min on ice. After washing with PBS, 100 μl TUNEL reaction mixture
was added onto samples and the plate was incubated in a humidiﬁed atmosphere
for 60 min at 37 °C in the dark. Then, cells were washed and incubated with mouse
VECAD anti-human antibody (Santa Cruz, Dallas, TX, USA Biotechnology) for 1 h
at room temperature. Anti-mouse Alexa Fluor 555 antibody (Molecular Probes,
Eugene, OR, USA) was used as secondary antibody. The nuclei of the cells were
stained with 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). After the
labeling, the cells were examined using LSM 710 laser scanning confocal
microscope (Carl Zeiss, Oberkochen, Germany). Information on antibodies is
given in Supplementary Table 1.
VEGFR-2 phosphorylation studies. OEPCs cultured on gelatin-coated plates were
starved in EBM-2 medium without supplements for 20 h, detached, and ﬁnally
suspended in EBM-2 medium containing MPs or VEGF-MPs at a ratio of 1:2 (cell:
particle). The cell suspension was then seeded as hanging drops (20,000 cells per
10 µl of methocel solution; this cell concentration was chosen to improve cell-MP
interaction for short times) in nonadhesive bacteriological dishes (Greiner Bio One
Ltd., Gloucestershire, UK) and incubated at 37 °C and 5% CO2 for up to 1 h. After
the incubation, the petri dishes were washed with cold EBM-2 medium and cells
were collected into pre-chilled centrifuge tubes. Cell suspensions were centrifuged
at 1000 rpm for 3 min at 4 °C. The medium was removed immediately, cells were
washed with ice-cold PBS containing sodium vanadate (0.2 mM) and cell lysis
buffer (1 ml; 1% NP-40 alternative, 20 mM Tris (pH 8.0), 137 mM NaCl, 10%
glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate, 10 mgml−1
aprotinin, 10 mgml−1 leupeptin) was added onto the cells. Samples were allowed to
sit on ice for 15 min. Before use, the lysates were centrifuged at 2000g for 5 min and
the supernatants were transferred into clean test tubes.
In order to determine the phosphorylation of VEGFR-2 by soluble VEGF,
OEPCs cultured on gelatin-coated plates were starved in EBM-2 medium without
supplements for 20 h. After that time, cells were activated with the same amount of
soluble VEGF as used for immobilized VEGF for up to 30 min. The cell culture
medium was removed, cells were washed with ice-cold PBS containing 0.2 mM
sodium vanadate, lyzed and analyzed as described above.
Cell lysates were evaluated using phosho and total VEGFR-2 ELISA kits (R&D
Systems) and the ratio of phospho/total VEGFR-2 was calculated according to
manufacturer’s instructions. The results were normalized by the cell culture control
(for soluble VEGF samples) or uncoated particles (for conjugated-VEGF samples)
for each experiment.
For western blots, total protein concentration from the lysates was determined
by BCA assay, and samples were treated with SDS-PAGE buffer (6× concentrated:
350 mM Tris, 10% (w/v) SDS, 30% (v/v) glycerol, 0.6 M DTT, 0.06% (w/v)
bromophenol blue), boiled for 5 min at 95 °C, and stored at −20 °C until used
for western blotting. Then, proteins (40 μg of total protein) were resolved in 15%
SDS-PAGE and then transferred to polyvinylidene diﬂuoride (PVDF) membranes
with 0.45 μm pore size in the following conditions: 300 mA, 90 min at 4 °C in a
solution containing 10 mM 3-[Cyclohexylamino]-1-propanesulfonic acid (CAPS)
and 20% methanol, pH 11. Membranes were blocked in Tris buffer saline
containing 5% low-fat milk and 0.1% Tween 20 (Sigma-Aldrich) for 1 h at RT and
then incubated overnight at 4 °C with the primary antibodies (rabbit anti-Tyr1175
(Santa Cruz, Dallas, TX, USA), rabbit anti-Tyr1214 (Santa Cruz) or mouse
anti-VEGFR-2 (Abcam, Cambridge, UK)) diluted 100 times in 1% TBS-Tween and
0.5% low-fat milk. After rinsing three times with TBS-T 0.5% low-fat milk,
membranes were incubated for 1 h at RT, with an alkaline phosphatase-linked
secondary anti-rabbit or anti-mouse antibody 1:20,000 in 1% TBS-T and 0.5%
low-fat milk (GE Healthcare, Buckinghamshire, UK). Protein immunoreactive
bands were visualized in a Versa-Doc Imaging System (model 3000, BioRad
Laboratories, CA), following incubation of the membrane with ECF reagent
(GE Healthcare) for 5 min. Densitometric analyses were performed by using the
ImageQuant software. Uncropped gel images are given in Supplementary Fig. 12.
Akt and p38 phosphorylation studies. The OEPC aggregates with soluble
VEGF and VEGF-conjugated MPs were prepared as described on “VEGFR-2
phosphorylation studies” section with modiﬁcations. Brieﬂy, OEPCs cultured on
gelatin-coated plates were starved in EBM-2 medium without supplements for 24
h, detached by using TrypLETM Express (Invitrogen), and suspended in EBM-2
medium containing soluble VEGF or VEGF-conjugated MPs at a ratio of 1:1
(cell:particle). The cell suspension was then seeded as hanging drops in non-
adhesive bacteriological dishes (Greiner Bio One Ltd.) and incubated at 37 °C and
5% CO2 for up to 1 h. After the incubation, the petri dishes were washed with cold
EBM-2 medium and cells were collected into pre-chilled centrifuge tubes. Cell
suspensions were centrifuged at 1000 rpm for 3 min at 4 °C. The medium was
removed immediately, cells were washed with ice-cold PBS containing sodium
vanadate (0.2 mM) and RIPA cell lysis buffer (Enzo, Farmingdale, NY, USA; 50
mM TRIS-hydrogen chloride, pH 7.4, containing 150 mM sodium chloride, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS)
containing protease inhibitor cocktail (Sigma-Aldrich) and 1 mM PMSF was added
onto the cells. Samples were ﬂash-frozen in liquid nitrogen. Before use, the lysates
were centrifuged at 2000 g for 5 min and the supernatants were transferred into
clean test tubes. Three million cells were used per condition. Cell lysates were
evaluated using phosho and total p38 and Akt ELISA kits (Invitrogen and Enzo)
according to the manufacturer’s instructions.
Ultrastructural analysis of cell aggregates. OEPC aggregates were ﬁxed in 2.5%
glutaraldehyde buffered with 0.05M sodium cacodylate, postﬁxed in 1.0% osmium
tetroxide and dehydrated in a graded series of ethanol27, 46. Micrographs were
taken with a ZEISS EM-10 electron microscope at 80 kV.
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Single cell calcium measurements. OEPCs growing in T75 ﬂasks were detached
and transferred onto 1% (w/v) gelatin-coated 10 mm coverslips. Cells were
incubated at 37 °C and 5% CO2 for 1 day, after which the cell culture medium was
removed and cells were starved in M200 medium without supplements for 20 h.
After removal of the cell culture medium, cells were loaded for 40 min at 37 °C with
5 µM Fura-2 AM (Invitrogen, Carlsbad, CA, USA), 0.1% (w/v) fatty acid-free BSA,
and 0.02% (w/v) pluronic acid F-127 in Krebs buffer (132 mM NaCl, 1 mM KCl, 1
mM MgCl2, 2.5 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH 7.4). In VEGFR-2
inhibition experiments, cells were co-incubated with Vatalanib (100 nM;
SelleckChem, Kirby Drive, Houston, TX, USA). After a 30 min post-loading period
at room temperature (RT), the coverslip was mounted on RC-25 chamber in a PH3
platform (Warner Instruments, Hamden, CT, USA) on the stage of an inverted
Axiovert 200 ﬂuorescence microscope (Carl Zeiss)47. Cells (~10 cells per ﬁeld) were
perfused with Krebs and stimulated by applying 100 µM histamine, 500 ng ml−1
soluble VEGF (100 ng in 200 µl Krebs solution), 2 × 105 uncoated particles or
2 × 105 VEGF-coated MPs (in 200 µl Krebs solution) by a fast pressurized (95% air,
5% CO2 atmosphere) system (AutoMate Scientiﬁc Inc., Berkeley, CA, USA).
[Ca2+]i was evaluated by quantifying the ratio of the ﬂuorescence emitted at
510 nm following alternate excitation (750 ms) at 340 and 380 nm, using a Lambda
DG4 apparatus (Sutter Instrument, Novato, CA, USA) and a 510 nm long-pass
ﬁlter (Carl Zeiss) before ﬂuorescence acquisition with a 40× objective and a
CoolSNAP digital camera (Roper Scientiﬁc, Tucson, AZ, USA). Acquired values
were processed using the MetaFluor software (Universal Imaging, Downingtown,
PA, USA).
Determination of ATP production and caspase 9 activity. Cellular viability was
determined using the CellTiter-Glo® luminescent cell viability assay (Promega,
Madison, WI, USA) according to manufacturer’s instructions. In this assay, the
luminescence signal increases with the number of viable cells in culture. The assay
is based on the ATP present in the culture, which indicates the presence of
metabolically active cells. The OEPC aggregates were prepared as described in
previous sections. Equal volumes of CellTiter-Glo® reagent and cell culture
medium were mixed in each well and incubated at room temperature for 2 min
on an orbital shaker to induce cell lysis. Then, the cells were transferred into
opaque-walled multiwell plates and luminescence measurements were done using a
LUMIstar Luminometer (BMG LABTECH, Ortenberg, Germany). The medium
without cells was used as a blank control.
The amount of apoptotic cells was determined using Caspase-Glo® 9 assay
(Promega). The assay depends on the generation of a “glow-type” luminescent
signal produced by the luciferase reaction between luminogenic caspase-9 substrate
and caspase-9 enzyme present in the cells. The assay was performed as described
previously, in “CellTiter-Glo® luminescent cell viability assay” part.
Matrigel assay. Angiogenesis µ-slides (IBIDI GmbH, Munich, Germany) were
coated with Matrigel (10 μl per well; BD Biosciences, San Diego, CA, USA) and
incubated for 30 min at 37 °C. The OEPCs growing on T75 ﬂask in EGM-2
medium were detached, suspended in serum-reduced (1% FBS) EGM-2 medium
without VEGF (50 μl; 1 × 105 cells ml−1) and seeded on top of polymerized
Matrigel. For the conditions with unconjugated and VEGF-conjugated MPs, the
OEPCs were mixed with MPs at a ratio of 1:1 (cell:particle) and the cell-particle
suspension was seeded on top of polymerized Matrigel after 5–10 min incubation
to promote cell-particle interaction. For soluble VEGF condition, 50 ng ml−1 VEGF
was used. Cells were incubated under hypoxia conditions (0.5% O2), with 5% CO2.
Sprout formation was evaluated by phase contrast microscopy (Zeiss Axiovert 40C,
Carl Zeiss) 12 and 60 h after the cell seeding.
VEGFR-2 stainings. For VEGFR-2 stainings, 10,000 OEPCs per well were seeded
on gelatin-coated 96-well μPlates from IBIDI (Munich, Germany). After overnight
incubation at 37 °C in 5% CO2, the cells were treated with VEGF-conjugated MPs
(1:2, cell:bead ratio) or with same amount of soluble VEGF for different time points
(i.e., 10, 30, 60, and 120 min). After incubations, the media were removed; cells
were washed with PBS and ﬁxated with 4% paraformaldehyde (EMS) for 15–20
min at room temperature. After permeabilizing the cells with 0.1% (v/v) Triton
X-100 (Sigma-Aldrich) for 10 min, and blocking for 30 min with 1% (w/v) BSA
solution (Sigma-Aldrich), the cells were stained for 1 h with the primary mouse
VEGFR-2 (Abcam) and rabbit ZO-1 (Carlsbad, CA, USA) anti-human antibodies.
Anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 555 antibodies (Molecular
Probes, Eugene, OR, USA) were used as secondary antibodies. The nuclei of the
cells were stained with DAPI (Sigma-Aldrich). After the labeling, the cells
were examined using LSM 710 laser scanning confocal microscope (Carl Zeiss).
Information about antibodies is given on Supplementary Table 1.
In vivo subcutaneous transplantation. The Experimental Animal Committee of
MIT approved all animal procedures. OEPC aggregates containing GFP-expressing
OEPCs (1 × 106; Passage 5; Angio-Proteomie, Boston, MA, USA) with or without
1 × 106 MPs were harvested, washed with EC basal medium, centrifuged and
mixed in 200 µl ﬁbrinogen (ﬁnal concentration 10 mgml−1). Thrombin (ﬁnal
concentration 2 Uml−1) was added to the mixture and the solution rapidly injected
subcutaneously on lateral to the abdominal midline region of nude mice. Mice were
imaged under isoﬂurane anesthesia, by an IVIS® Spectrum in vivo imaging system
(Xenogen Corporation, Alameda, CA, USA) up to 20 days. IVIS images were taken
and analyzed using Caliper Living Imaging Software. The following parameters
have been used: (i) a laser excitation at 490 nm and an emission ﬁlter at 510 nm,
(ii) an exposure time of 0.5 s per image, and (iii) an image ﬁeld of 12.5 × 12.5 cm.
For miRNA isolations, animals were sacriﬁced 1 day after the surgery and the
constructs were collected. The samples were washed with PBS, mounted in OCT
compound (VWR, Radnor, PA, USA), and frozen in liquid nitrogen. Sections
were cut at 20 μm on a Leica cryostat and immediately transferred to lysis buffer
containing β-mercaptoethanol. The samples were disrupted with 5 mm stainless
steel beads (Qiagen, Hilden, Germany) for 2 min at 25 Hz and for 2 min at 20 Hz
using a Qiagen TissueLyser. miRNA was isolated from the samples as described in
the following sections.
miRNA microarray. Total RNA was isolated using the absolutely RNA miRNA
kit (400814, Agilent Technologies, Santa Clara, CA, USA) according to the
manufacturer’s instructions. RNA quality was assessed by an Agilent 2100
Bioanalyser (G2943CA), using an Agilent RNA 6000 Nano kit (5067–1511).
Each RNA sample (100 ng) was hybridized with an Agilent human microRNA
microarray (G4471A, Agilent Technologies). MicroRNA labeling, hybridization,
and washing steps were carried out by following Agilent’s instructions. Agilent
microRNA assays integrate eight individual microarrays on a single glass slide.
Each microarray includes ~15k features containing probes sourced from the
miRBase public database. The probes are 60-mer oligonucleotides directly
synthesized on the array. The human miRNA microarray version3 contains probes
for 866 human and 89 human viral microRNAs from the Sanger miRBase v12.048.
The microarrays were scanned by an Agilent B Scanner (G2565BA). The raw
data were analyzed using BRB-ArrayTools v3.4.0 developed by Dr. Richard Simon
and BRB-ArrayTools development team49. This analysis generates a median
normalized data set that is subjected to a statistical study and clustering using MeV
software28. The differentially expressed miRNAs obtained from MeV were used to
calculate the M-value and Fold-change variation. It was considered as differentially
expressed miRNA a variation equal or higher than 2× between the different
conditions. The data were uploaded on Gene Expression Omnibus (GEO Accession
Number: GSE75899).
mRNA sequencing. Total RNA from OEPCs treated with antagomiR-17 or control
antagomiR for 48 h was isolated using mirVanaTM miRNA isolation kit (Ambion,
Carlsbad, CA, USA) according to the manufacturer’s instructions. The RNA
samples were shipped to Exiqon (Vedbaek, Denmark) in dry ice. RNA sample
quality control, library preparation, library quality control and quantiﬁcation and
data analyses were performed by Exiqon (Vedbaek).
The library preparation was done using TruSeq® Stranded mRNA Sample
preparation kit (Illumina Inc., San Diego, CA, USA). The starting material (500 ng)
of total RNA was mRNA enriched using the oligodT bead system (manufacturer).
The isolated mRNA was subsequently fragmented using enzymatic fragmentation.
Then ﬁrst strand synthesis and second strand synthesis were performed and the
double stranded cDNA was puriﬁed (AMPure XP; Beckman Coulter, Brea, CA,
USA). The cDNA was end repaired, 3′ adenylated and Illumina sequencing
adaptors ligated onto the fragments ends, and the library was puriﬁed (AMPure
XP). The mRNA stranded libraries were pre-ampliﬁed with PCR and puriﬁed
(AMPure XP). The libraries’ size distribution was validated and quality inspected
on a Bioanalyzer high sensitivity DNA chip (Agilent Technologies). High quality
libraries were quantiﬁed using qPCR, the concentration normalized and the
samples pooled according to the project speciﬁcation (number of reads). The
library pool(s) were re-quantiﬁed with qPCR and optimal concentration of the
library pool used to generate the clusters on the surface of a ﬂowcell before
sequencing on Nextseq500 instrument using High Output sequencing kit (50
cycles) according to the manufacturer instructions (Illumina Inc.). The data were
uploaded on Gene Expression Omnibus (GEO Accession Number: GSE76663).
Quantitative RT-PCR analyses of miRNA. Total RNA was isolated using the
absolutely RNA miRNA kit (400814; Agilent Technologies) according to the
manufacturer’s instructions. The cDNA was synthesized using the NCode™miRNA
ﬁrst-strand cDNA synthesis kit (Invitrogen). The expression of selected miRNAs
was assessed by quantitative RT-PCR (qRT-PCR) (7500 Fast Real-Time PCR
System, Applied Biosystems, Carlsbad, CA, USA) using KAPA SYBR® FAST qPCR
Master Mix (Kapa Biosystems, Wilmington, MA, USA). To normalize the
expression levels of target miRNAs, the small nucleolar RNA C/D box 48
(SNORD48) and 5S ribosomal RNA were used as a control (housekeeping). Primer
sequences are given in Supplementary Table 2.
qRT-PCR analyses of total RNA in cell aggregates. Total RNA was isolated
from OEPCs and HUVECs under different conditions using mirVanaTM miRNA
isolation kit (Ambion) according to the manufacturer’s instructions. In all cases,
cDNA was prepared from 1 μg total RNA using Taqman Reverse transcription
reagents (Applied Biosystems, Foster City, CA, USA). Quantitative real time PCR
(qRT-PCR) was performed using KAPA SYBR FAST qPCR Master Mix (Kapa
Biosystems) and the detection was carried out in a 7500 Fast Real-Time PCR
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System (Applied Biosystems, Foster City, CA, USA). Quantiﬁcation of target genes
was performed relatively to the reference gene (U6): relative expression = 2
[−(Ctsample−Cthousekeeping)]. Primer sequences are given as supporting information
(Supplementary Table 2).
Transfection of OEPCs. OEPCs were transfected at 40–60% conﬂuency using
Lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s protocols.
Inhibition of miR-17 was achieved by transfection of cells with 50 nM miRIDIAN
Hairpin Inhibitor (Dharmacon Inc., Lafayette, CO, USA). 50 nM anti-miR
negative control from Ambion was used as control in all transfection experiments.
siRNA-mediated silencing of ZNF652 and CDKN1A was obtained using 40 nM
ON-TARGETplus siRNAs (Dharmacon Inc.) against these targets. After 2 days of
transfection, cells in 96-well plates were washed and the cell culture medium
was replaced by EBM-2 and cells were incubated under normoxia and hypoxia
conditions (0.1% O2), with 5% CO2. After 48 h, survival assay (Presto Blue
Cell Viability Reagent; Thermo Fisher Scientiﬁc) was performed according to
manufacturer’s instructions. For Matrigel assay, the cells were detached after
transfection, suspended in serum-reduced (1% FBS) EGM-2 medium without
VEGF (50 μl; 2 × 105 cells ml−1) and seeded on top of polymerized Matrigel. Cells
were incubated under normoxia and hypoxia conditions (0.1% O2), with 5% CO2.
Sprout formation was evaluated by phase contrast microscopy (Zeiss Axiovert 40C,
Carl Zeiss) or INCELL Analyzer 2200 (GE Healthcare) 48 h after the cell seeding.
Stainings for CDKN1A. For stainings, the cells were detached after transfection,
suspended in EGM-2 medium (50 μl; 5 × 105 cells ml−1) and seeded onto
gelatin-coated angiogenesis µ-slides (IBIDI GmbH, Munich, Germany). After 24 h
in hypoxia, cells were ﬁxated with 4% paraformaldehyde (EMS) for 15–20 min at
room temperature. After permeabilizing the cells with 0.1% (v/v) Triton X-100
(Sigma-Aldrich) for 10 min, whenever required, and blocking for 30 min with
1% (w/v) BSA solution (Sigma-Aldrich), the cells were stained for 1 h with
the primary rabbit CDKN1A (Santa Cruz, Dallas, TX, USA Biotechnology)
anti-human antibody. The binding of primary antibody to speciﬁc cells was
detected with anti-rabbit IgG Cy3 (Jackson Immunoresearch) conjugates. The
nuclei of the cells were stained with DAPI (Sigma-Aldrich). After the labeling, the
cells were examined with a ﬂuorescence microscope (Carl Zeiss).
In order to determine the downregulation of CDKN1A in protein level after
siRNA transfection, the cells were co-transfected with siRNAs and miRNAs in
gelatin-coated 24-well μPlates from IBIDI (Munich, Germany) as described in the
previous section. After 48 h of transfection, the medium was removed; cells were
washed with PBS and ﬁxated with 4% paraformaldehyde (EMS) for 15–20 min at
room temperature. After permeabilizing the cells with 0.1% (v/v) Triton X-100
(Sigma-Aldrich) for 10 min, and blocking for 30 min with 1% (w/v) BSA solution
(Sigma-Aldrich), the cells were stained for 1 h with the primary rabbit CDKN1A
(Santa Cruz, Dallas, TX, USA Biotechnology) anti-human antibody. Anti-rabbit
Alexa Fluor 488 antibody (Molecular Probes, Eugene, OR, USA) was used as
secondary antibody. The nuclei of the cells were stained with DAPI (Sigma-
Aldrich). After the labeling, the cells were examined using LSM 710 laser scanning
confocal microscope (Carl Zeiss). Information about antibodies is given on
Supplementary Table 1.
Hindlimb ischemia experiments. Experiments were performed in accordance
with the Animal (Scientiﬁc Procedures) Act (UK) 1986 prepared by the Institute of
Laboratory Animal Resources and under the auspices of UK Home Ofﬁce Project
and Personal License. Experiments were approved by the University of Bristol
Ethical Review Committee. Before transplantation, the OEPCs were transfected
with 50 nM control antagomiR (Ambion) or antagomiR-17 (miRIDIAN Hairpin
Inhibitor; Dharmacon Lafayette, CO, USA) for 48 h using Lipofectamine RNAiMax
(Invitrogen) as described in the previous sections. Female CD1 nude mice
(age 14 weeks) were injected with OEPCs (3 × 106) transfected with antagomiR-17
(n= 12), control antagomiR (n= 12), or EBM-2 (n= 12) after surgery to induce
unilateral limb ischemia under general anesthesia. Limb ischemia was obtained by
occlusion of the left femoral artery. Mice were sacriﬁced 3 weeks after surgery. The
superﬁcial blood ﬂow to both feet was measured using high-resolution laser color
Doppler imaging system at 30 min and days 2, 7, 14, and 21 after limb ischemia.
Blood ﬂow recovery was calculated as a ratio of ischemic over contralateral foot
blood ﬂow. After the last Doppler analysis (at day 21 after surgery), mice were
perfusion-ﬁxed under terminal anesthesia and limb muscles were harvested for
immunohistochemical analyses.
Histology. The functional impact antagomiR-17 treatment on CD1 nude mice was
assessed by measuring capillary density in the adductor muscle. Eight micrometer
thick muscle sections were stained using biotin-conjugated Griffonia simplicifolia
isolectin B4 conjugate (I21414) and streptavidin-conjugated Alexa Fluor-488
(S11223; both from Molecular Probes, Eugene, OR, USA) to detect capillaries.
Nuclei were stained with DAPI. The slides were mounted using Fluoromount-G™
(eBioscience, San Diego, CA, USA). The relative amount of positive cells was
counted in 8 randomly selected high-power ﬁelds (magniﬁcation 20×) using a Zeiss
inverted ﬂuorescence microscope. Analyses were performed using muscles from
eight mice per group. Capillary density was expressed in number per mm2.
3′UTR Luciferase assay. 7000 HEK293 cells were seeded in each well of a 96-well
black clear-bottom plate (Corning Inc., Corning, NY, USA) and incubated over-
night at 37 °C (5% CO2, 95% humidity). The cells were co-transfected with 50 nM
miRNA mimics (control miRNA or miR-17; both from Ambion) and 100 ng of
each 3′UTR luciferase reporter vectors (empty vector, CDKN1A vector or ZNF652
vector; all from Active Motif, Carlsbad, CA, USA) using DharmaFECT Duo
Transfection Reagent (Dharmacon Inc.)50. After 24 h of transfection, luciferase
activity was measured using LightSwitch Luciferase Assay Reagents (SwitchGear
Genomics, Menlo Park, CA, USA) according to the manufacturer’s instructions.
GloMax-96 Microplate Luminometer from Promega was used for the
measurements.
Statistical analysis. An unpaired t-test or one-way analysis of variance
(ANOVA) analysis of variance with Bonferroni post test were performed
as statistical tests using GraphPad Prism software (San Diego, CA, USA, http://
www.graphpad.com/). Results were considered signiﬁcant when P< 0.05. Data are
shown as mean± SEM.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles or
from the corresponding author upon reasonable request. All microarray and
sequencing data have been deposited in the Gene Express Omnibus public database
(National Center for Biotechnology Information) under accession codes: GSE75899
(miRNA microarray) and GSE76663 (mRNA sequencing).
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